• News


proACTINA at EANM2018

proACTINA SA, represented by Dr. Alex Strongilos (President and CEO), will be present at the 31st Annual EANM Congress, which will be held in the city of Düsseldorf, Germany. From 13 to 17 October 2018, the Congress will host a unique gathering of clinical scientists, technologists, physicians, physicists, industry representatives and researchers.

Dr A. Strongilos, will have the chance to meet with international KOLs, interact with existing and potential business partners and be updated on the latest developments in the field of Nuclear Medicine.

To book a meeting, please send an email at This email address is being protected from spambots. You need JavaScript enabled to view it. with your name, position, company and availability (14-16/10).

Looking forward to meeting you at the EANM congress.


proACTINA exhibiting at BIO International Convention in San Diego/USA

Pro-ACTINA is proud to be exhibiting during BIO International Convention in San Diego, selected as one of the 15 European SMEs Instrument Ambassadors under the EASME Overseas Trade Fairs program aiming to support international commercialization of EU innovation. From 19-22 June 2017, pro-ACTINA will have the unique opportunity to gain first-hand experience of the US market and establish business contacts with local companies via the trade fair and business meetings.

The BIO International Convention (BIO) attracts 16,000 biotechnology and pharma leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships.


[H2020 - SME Instrument – Overseas Trade Fairs Pavilion]

GLIOMARK 1 Phase II clinical study currently recruiting patients

GLIOMARK1 Phase II clinical study (EudraCT No: 2015-005573-21), as part clinical development of GLIOMARK project, is currently recruiting patients. The study is entitled: "Exploratory phase II study in patients after treatment of high grade brain tumors to assess the technical performance of Tc-99m tetrofosmin for differentiation of recurrence versus radiation necrosis"

Phase II clinical study (Gliomark1) successfully completed


proACTINA SA, on behalf of the GLIOMARK consortium, is delighted to announce that the Gliomark1 Phase II clinical study has been successfully completed.

Gliomark1: Phase II exploratory study assessing the technical performance of 99mTc-tetrofosmin for the differentiation of tumour recurrence vs. radiation-necrosis in patients with high grade brain tumours following initial treatment (EudraCT No.: 2015-005573-21, ClinicalTrials.gov ID: NCT02971319).

Sponsor: ProACTINA SA

The study, conducted in 6 large glioma centers in Europe, met all end-points, regarding both technical and diagnostic performance of 99mTc-tetrofosmin, and sets a strong basis for the design of a successful phase III confirmatory study.

The sponsor wishes to thank all the Principal Investigators and their dedicated teams, as well as our highly experienced team of Medical Advisors for their impactful contribution and commitment to bringing the study to its successful completion.

Dr Alex Strongilos, CEO of proACTINA, stated that “the successful completion of the phase II study is a major advancement towards the completion of this ambitious project and it constitutes a very strong foundation for the upcoming Phase III study”.

Dr Daniel Schubart, Managing Director of ConsulTech, stated that “We have now reached a very important milestone of the GLIOMARK project and we are very enthusiastic about this significant achievement”.

Further information is available at www.gliomark.eu

Gliomark1 Phase II clinical study was part of GLIOMARK project, which receives funding from the European Union´s Horizon 2020 Research and Innovation, SME Instrument Phase II programme (GA No. 673737).


EC grants Orphan Drug Designation to proACTINA for tetrofosmin for diagnosis of Glioma

Athens, 26/10/2016

proACTINA SA, a research-driven and innovation-focused Small-Medium Enterprise in Athens-Greece, today announced that European Commission (EC) has granted Orphan Designation for tetrofosmin for the diagnosis of glioma, following a positive opinion by European Medicines Agency (EMA). The Decision was published in the Community Register of Orphan Medicinal Products and the product has received EU orphan designation number: EU/3/16/1764

For the full press release see: Orphan designation press release


  • 1
  • 2

Contact us

Address:20, Delfon Street
151 25 Marousi,
Email:This email address is being protected from spambots. You need JavaScript enabled to view it.